How to Use Tesamorelin
Complete guide to Tesamorelin dosing, administration, timing, and protocol recommendations.
Quick Overview
Tesamorelin is a stabilized analog of growth-hormone-releasing hormone (GHRH 1-44) with a chemical modification that protects it from rapid breakdown. It is FDA-approved (brand name Egrifta) to reduce excess visceral abdominal fat in people with HIV-associated lipodystrophy, which makes it one of the few growth-hormone-axis peptides with a real approval behind it. Its evidence base is solid for that specific population and thinner for the general anti-aging and fat-loss uses it gets promoted for online.
Dosing Guidelines
Common Dose
2 mg daily (F8: 1.28 mg daily)
Frequency
Once daily
Dose Range
1.28-2 mg daily
Note: FDA-approved dose is 2 mg (original) or 1.28 mg (F8/Egrifta WR formulation). Inject subcutaneously in abdomen. F8 requires weekly reconstitution vs daily.
Administration Method
Subcutaneous injection
Best Time to Take
Before bed (fasted)
FDA-approved GHRH analog works best on empty stomach, timed with natural GH release during sleep.
Protocol Duration
Indefinite for approved indication
Possible Side Effects
Not everyone experiences these. Individual responses vary.
- •Injection site reactions (common)
- •Joint pain
- •Peripheral edema
- •Pain in extremities
- •Muscle pain
Frequently Asked Questions
What is the recommended dose for Tesamorelin?
2 mg daily (F8: 1.28 mg daily)
How do you administer Tesamorelin?
Subcutaneous injection
When is the best time to take Tesamorelin?
Before bed (fasted)
How long should you use Tesamorelin?
Indefinite for approved indication
This information is for educational purposes only. Always consult with a healthcare professional before using any peptide. Dosing information is based on research literature and community reports, not medical advice.